Adjuvant facilitates tolerance induction to factor VIII in hemophilic mice through a Foxp3-independent mechanism that relies on IL-10

Blood

Volumn 121, Issue 19, 2013, Pages 3936-3945

  Oliveira, Vanessa G ^a,b   Agua Doce, Ana ^a,b   Graca, Luis ^a,b   Lafaille, Juan J ^c  

^a INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

^b INSTITUTO GULBENKIAN DE CIÊNCIA   (Portugal)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; IMMUNOGLOBULIN G2B; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 10; INTERLEUKIN 10 RECEPTOR; OKT 4; OVALBUMIN; RECOMBINANT BLOOD CLOTTING FACTOR 8; T LYMPHOCYTE RECEPTOR; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA; ALUMINUM POTASSIUM SULFATE; ALUMINUM SULFATE; CD4 ANTIGEN; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, MOUSE; IL10 PROTEIN, MOUSE; MONOCLONAL ANTIBODY;

ADOPTIVE TRANSFER; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ANTIGEN SPECIFICITY; ARTICLE; AUTOIMMUNITY; B LYMPHOCYTE SUBPOPULATION; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; DRUG ADSORPTION; DRUG HALF LIFE; HEMOPHILIA A; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOLOGICAL TOLERANCE; IN VIVO STUDY; LIMIT OF DETECTION; MOUSE; NONHUMAN; OSMOTIC PUMP; PRIORITY JOURNAL; REGULATORY MECHANISM; REGULATORY T LYMPHOCYTE; REPEATED DRUG DOSE; SUSTAINED DRUG RELEASE; T CELL DEPLETION; T LYMPHOCYTE SUBPOPULATION; ANIMAL; BAGG ALBINO MOUSE; C57BL MOUSE; DRUG COMBINATION; DRUG EFFECT; DRUG SCREENING; GENETICS; IMMUNOLOGY; METABOLISM; MOUSE MUTANT; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ADJUVANTS, IMMUNOLOGIC; ALUM COMPOUNDS; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD4; DRUG COMBINATIONS; DRUG EVALUATION, PRECLINICAL; FACTOR VIII; FORKHEAD TRANSCRIPTION FACTORS; HEMOPHILIA A; IMMUNE TOLERANCE; INTERLEUKIN-10; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, KNOCKOUT; SIGNAL TRANSDUCTION; T-LYMPHOCYTES, REGULATORY;

MLCS; MLOWN;

EID: 84880459064     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-09-457135     Document Type: Article

References (48)

1. Astermark J, Lacroix-Desmazes S, Reding MT. Inhibitor development. Haemophilia. 2008; 14(suppl 3):36-42.
2. Lillicrap D. The role of immunomodulation in the management of factor VIII inhibitors. Hematology (Am Soc Hematol Educ Program). 2006:421-425.
3. Dimichele D. Immune tolerance therapy for factor VIII inhibitors: moving from empiricism to an evidence-based approach. J Thromb Haemost. 2007;5(suppl 1):143-150.
4. Fox RA, Neufeld EJ, Bennett CM. Rituximab for adolescents with haemophilia and high titre inhibitors. Haemophilia. 2006;12(3):218-222.
5. Kurth MA, Dimichele D, Sexauer C, et al. Immune tolerance therapy utilizing factor VIII/von Willebrand factor concentrate in haemophilia A patients with high titre factor VIII inhibitors. Haemophilia. 2008;14(1):50-55.
6. Kempton CL, White GC II. How we treat a hemophilia A patient with a factor VIII inhibitor. Blood. 2009;113(1):11-17.
7. Graca L, Le Moine A, Cobbold SP, Waldmann H. Antibody-induced transplantation tolerance: the role of dominant regulation. Immunol Res. 2003; 28(3):181-191.
8. Waldmann H, Adams E, Cobbold S. Reprogramming the immune system: co-receptor blockade as a paradigm for harnessing tolerance mechanisms. Immunol Rev. 2008;223:361-370.
9. Cobbold SP, Castejon R, Adams E, Zelenika D, Graca L, Humm S, Waldmann H. Induction of foxP31 regulatory T cells in the periphery of T cell receptor transgenic mice tolerized to transplants. J Immunol. 2004;172(10):6003-6010.
10. Graca L, Le Moine A, Lin CY, Fairchild PJ, Cobbold SP, Waldmann H. Donor-specific transplantation tolerance: the paradoxical behavior of CD41CD251 T cells. Proc Natl Acad Sci USA. 2004;101(27):10122-10126.
11. Lin CY, Graca L, Cobbold SP, Waldmann H. Dominant transplantation tolerance impairs CD81 T cell function but not expansion. Nat Immunol. 2002;3(12):1208-1213.
12. Reipert BM, Sasgary M, Ahmad RU, Auer W, Turecek PL, Schwarz HP. Blockade of CD40/ CD40 ligand interactions prevents induction of factor VIII inhibitors in hemophilic mice but does not induce lasting immune tolerance. Thromb Haemost. 2001;86(6):1345-1352.
13. Salooja N, Kemball-Cook G, Tuddenham EG, Dyson J. Use of a non-depleting anti-CD4 antibody to modulate the immune response to coagulation factors VIII and IX. Br J Haematol. 2002;118(3):839-842.
14. Peng B, Ye P, Blazar BR, Freeman GJ, Rawlings DJ, Ochs HD, Miao CH. Transient blockade of the inducible costimulator pathway generates long-term tolerance to factor VIII after nonviral gene transfer into hemophilia A mice. Blood. 2008; 112(5):1662-1672.
15. Bi L, Lawler AM, Antonarakis SE, High KA, Gearhart JD, Kazazian HH Jr. Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A. Nat Genet. 1995;10(1):119-121.
16. Curotto de Lafaille MA, Muriglan S, Sunshine MJ, et al. Hyper immunoglobulin E response in mice with monoclonal populations of B and T lymphocytes. J Exp Med. 2001;194(9): 1349-1359.
17. Qin SX, Wise M, Cobbold SP, Leong L, Kong YC, Parnes JR, Waldmann H. Induction of tolerance in peripheral T cells with monoclonal antibodies. Eur J Immunol. 1990;20(12):2737-2745.
18. Kasper CK, Aledort L, Aronson D, et al. Proceedings: A more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh. 1975;34(2):612.
19. Kool M, Fierens K, Lambrecht BN. Alum adjuvant: some of the tricks of the oldest adjuvant. J Med Microbiol. 2012;61(pt 7):927-934.
20. Lindblad EB. Aluminium adjuvants—in retrospect and prospect. Vaccine. 2004;22(27-28): 3658-3668.
21. HogenEsch H. Mechanisms of stimulation of the immune response by aluminum adjuvants. Vaccine. 2002;20(suppl 3):S34-S39.
22. Apostolou I, von Boehmer H. In vivo instruction of suppressor commitment in naive T cells. J Exp Med. 2004;199(10):1401-1408.
23. Graca L, Cobbold SP, Waldmann H. Identification of regulatory T cells in tolerated allografts. J Exp Med. 2002;195(12):1641-1646.
24. Kingsley CI, Karim M, Bushell AR, Wood KJ. CD251CD41 regulatory T cells prevent graft rejection: CTLA-4- and IL-10-dependent immunoregulation of alloresponses. J Immunol. 2002;168(3):1080-1086.
25. Regateiro FS, Howie D, Cobbold SP, Waldmann H. TGF-b in transplantation tolerance. Curr Opin Immunol. 2011;23(5):660-669.
26. Wood KJ, Bushell A, Hester J. Regulatory immune cells in transplantation. Nat Rev Immunol. 2012;12(6):417-430.
27. Hara M, Kingsley CI, Niimi M, et al. IL-10 is required for regulatory T cells to mediate tolerance to alloantigens in vivo. J Immunol. 2001; 166(6):3789-3796.
28. Couper KN, Blount DG, de Souza JB, Suffia I, Belkaid Y, Riley EM. Incomplete depletion and rapid regeneration of Foxp31 regulatory T cells following anti-CD25 treatment in malaria-infected mice. J Immunol. 2007;178(7):4136-4146.
29. Qadura M, Waters B, Burnett E, Chegeni R, Hough C, Othman M, Lillicrap D. Immunoglobulin isotypes and functional anti-FVIII antibodies in response to FVIII treatment in Balb/c and C57BL/ 6 haemophilia A mice. Haemophilia. 2011;17(2): 288-295.
30. Agua-Doce A, Graca L. Prevention of house dust mite induced allergic airways disease in mice through immune tolerance. PLoS ONE. 2011;6(7): e22320.
31. Kendal AR, Chen Y, Regateiro FS, et al. Sustained suppression by Foxp31 regulatory T cells is vital for infectious transplantation tolerance. J Exp Med. 2011;208(10):2043-2053.
32. Duarte J, Agua-Doce A, Oliveira VG, Fonseca JE, Graca L. Modulation of IL-17 and Foxp3 expression in the prevention of autoimmune arthritis in mice. PLoS ONE. 2010;5(5):e10558.
33. Thomson AW, Turnquist HR, Raimondi G. Immunoregulatory functions of mTOR inhibition. Nat Rev Immunol. 2009;9(5):324-337.
34. Moghimi B, Sack BK, Nayak S, Markusic DM, Mah CS, Herzog RW. Induction of tolerance to factor VIII by transient co-administration with rapamycin. J Thromb Haemost. 2011;9(8): 1524-1533.
35. Graca L, Thompson S, Lin CY, Adams E, Cobbold SP, Waldmann H. Both CD4(1)CD25(1) and CD4(1)CD25(-) regulatory cells mediate dominant transplantation tolerance. J Immunol. 2002;168(11):5558-5565.
36. van Maurik A, Wood KJ, Jones ND. Impact of both donor and recipient strains on cardiac allograft survival after blockade of the CD40-CD154 costimulatory pathway. Transplantation. 2002; 74(5):740-743.
37. Bach JF, Chatenoud L. A historical view from thirty eventful years of immunotherapy in autoimmune diabetes. Semin Immunol. 2011; 23(3):174-181.
38. Waters B, Qadura M, Burnett E, et al. Anti-CD3 prevents factor VIII inhibitor development in hemophilia A mice by a regulatory CD41 CD251-dependent mechanism and by shifting cytokine production to favor a Th1 response. Blood. 2009;113(1):193-203.
39. Zhang AH, Skupsky J, Scott DW. Effect of B-cell depletion using anti-CD20 therapy on inhibitory antibody formation to human FVIII in hemophilia A mice. Blood. 2011;117(7):2223-2226.
40. Benjamin RJ, Waldmann H. Induction of tolerance by monoclonal antibody therapy. Nature. 1986; 320(6061):449-451.
41. Gutstein NL, Seaman WE, Scott JH, Wofsy D. Induction of immune tolerance by administration of monoclonal antibody to L3T4. J Immunol. 1986; 137(4):1127-1132.
42. Moreland LW, Pratt PW, Mayes MD, et al. Double-blind, placebo-controlled multicenter trial using chimeric monoclonal anti-CD4 antibody, cM-T412, in rheumatoid arthritis patients receiving concomitant methotrexate. Arthritis Rheum. 1995; 38(11):1581-1588.
43. van Oosten BW, Lai M, Hodgkinson S, et al. Treatment of multiple sclerosis with the monoclonal anti-CD4 antibody cM-T412: results of a randomized, double-blind, placebo-controlled, MR-monitored phase II trial. Neurology. 1997; 49(2):351-357.
44. Horneff G, Winkler T, Kalden JR, Emmrich F, Burmester GR. Human anti-mouse antibody response induced by anti-CD4 monoclonal antibody therapy in patients with rheumatoid arthritis. Clin Immunol Immunopathol. 1991;59(1):89-103.
45. Kon OM, Sihra BS, Compton CH, Leonard TB, Kay AB, Barnes NC. Randomised, dose-ranging, placebo-controlled study of chimeric antibody to CD4 (keliximab) in chronic severe asthma. Lancet. 1998;352(9134):1109-1113.
46. Winsor-Hines D, Merrill C, O’Mahony M, et al. Induction of immunological tolerance/ hyporesponsiveness in baboons with a nondepleting CD4 antibody. J Immunol. 2004; 173(7):4715-4723.
47. Hausl C, Ahmad RU, Schwarz HP, Muchitsch EM, Turecek PL, Dorner F, Reipert BM. Preventing restimulation of memory B cells in hemophilia A: a potential new strategy for the treatment of antibody-dependent immune disorders. Blood. 2004;104(1): 115-122.
48. Lei TC, Scott DW. Induction of tolerance to factor VIII inhibitors by gene therapy with immunodominant A2 and C2 domains presented by B cells as Ig fusion proteins. Blood. 2005;105(12):4865-4870.